StockResearch Intelligence Weekly #25

1. Opening

This was a selective reset, not a broad liquidation. From the July 10 close through Friday, July 17, the S&P 500 fell 1.55% to 7,457.69, the Nasdaq Composite lost 2.90% to 25,520.24, and the Dow fell 0.93% to 52,146.42. The Russell 2000 declined 0.52%. The headline indices, however, disguised the real move: SOXX fell 10.24% and XLK lost 5.48%, while USO gained 14.04% and XLE rose 4.72%. Investors did not abandon equities wholesale. They cut the crowded AI-hardware complex and paid up for energy exposure and visible cash flows.

That split was decisive at the stock level. AMD fell 11.14%, Marvell Technology fell 19.99%, Nvidia lost 3.86%, and Broadcom fell 7.29%. S&P Global gained 4.72%, Chevron rose 6.22%, and Exxon Mobil gained 6.11%. The tape therefore became harder for autopilot exposure: a diversified index holder had a manageable week, while a portfolio concentrated in high-beta semiconductors had a much rougher one. AP’s July 17 market report also identified semiconductor weakness as a central driver of the session. AP market report

Last edition reinforced why entry discipline matters. Alphabet fell 2.91%, Walmart gained 0.30%, and Caterpillar fell 7.57% after we held it because it already traded above its mean target. Repligen, TransMedics, and Crocs gained 2.09%, 3.86%, and 3.28%, respectively. The lesson is not to grade a thesis by one week. It is to separate a strong business from a stock that is already priced for strength.

That is the filter for #25. We are not treating the semiconductor drawdown as a blanket dip-buying signal. LMT, SYK, and SPGI all offer a measurable 19.4%-23.3% gap to their mean targets, identifiable operating catalysts, and the latest model’s UP direction across 1D, 3D, and 7D. The model helps with timing and conviction; valuation, fundamentals, and earnings risk still decide the verdict. MOD’s 56.2% target gap earns a speculative allocation only, CAVA’s 124.5x forward P/E keeps it at HOLD, and IONQ’s expected loss keeps it out of the buy list.

2. Strengths

Earnings visibility still found buyers outside AI hardware. S&P Global gained 4.72% while the Nasdaq fell, and Chevron and Exxon Mobil rose 6.22% and 6.11%. Investors favored businesses with visible cash generation over the crowded chip trade. SPGI’s first-quarter revenue was $4.171 billion, operating income was $2.002 billion, and free cash flow was $1.010 billion. At $450.84, it is still 20.0% below its $541.22 mean target.
Defense offers a differentiated catalyst. Lockheed reports July 23, with consensus at $7.22 EPS and $19.365 billion of revenue. Its $627.10 mean target is 23.3% above the close, and its roughly 17.0x FY2026 P/E is reasonable. Negative $291 million of March-quarter free cash flow remains the caveat. The July 23 report must confirm program execution and cash conversion.
Healthcare remains a selective entry point. Stryker’s first-quarter revenue was $6.020 billion, operating income was $936 million, and free cash flow was $415 million. It trades 19.4% below its $381.79 mean target and reports July 30. SYK is above its 50-day average but below its 200-day average. That supports measured accumulation, not momentum buying.

3. Weaknesses

The semiconductor selloff is broad enough to demand patience. AMD fell 11.14%, Broadcom fell 7.29%, Marvell fell 19.99%, and SOXX lost 10.24%. The move does not prove AI demand has broken, but it does show how quickly valuation and expectations can reset. We need evidence on revenue, margins, customer budgets, and analyst targets before treating the decline as an entry point. This edition does not force a semiconductor name into the Top 3.
Energy strength raises the bar for rate-sensitive exposure. USO rose 14.04%, while GLD fell 2.28% and TLT gained only 0.06%. That weakens the assumption that falling rates will automatically support long-duration growth. Flash PMI on July 24, the July 28-29 FOMC meeting, and July 30 GDP data are the next valuation checkpoints.
Low-cap upside still comes with valuation and execution risk. MOD’s 56.2% target gap is supported by strong growth, but its roughly 44.3x FY2026 P/E and margin pressure keep it at SPEC. BUY. CAVA’s roughly 124.5x FY2026 P/E keeps it at HOLD. IONQ’s expected losses and negative free cash flow outweigh its wide target gap, leaving it as NO TRADE.

4. Weekly Market Recap

StockResearch Intelligence Weekly #25, graphic 2

5. Top 3 Stock Picks for Long-Term Investment

StockResearch Intelligence Weekly #25, graphic 3

1. Lockheed Martin (LMT) — BUY

Lockheed is the cleanest way in this edition to take exposure to defense spending and mission-critical programs without needing the semiconductor group to stabilize first. Its March-quarter revenue of $18.021 billion and operating income of $2.063 billion establish a tangible base. Diluted EPS was $6.44. The July 23 report is the immediate test, with consensus at $7.22 EPS and $19.365 billion of revenue. The underlying reason to own the stock is not a one-quarter beat. It is that the company operates in programs where demand, backlog conversion, and government budgets can create longer visibility than the market’s current technology cycle.
At $508.77, LMT is below both its 50-day average of $520.85 and 200-day average of $542.53. The mean target is $627.10, a 23.3% gap, with published targets ranging from $517 to $700. The mean target and reasonable forward multiple make the reward compelling enough for a BUY, but the low target remains a reminder that execution risk is real.
The latest 1D prediction is UP 0.05% to $509.01 at 54.38% confidence for July 20. The 3D prediction is UP 0.16% to $509.59 at 51.89% confidence for July 22. The 7D prediction is UP 1.51% to $516.44 at 80.64% confidence for July 28. We agree with the model’s positive direction, but only the 7D reading reaches our high-conviction threshold. The long-term BUY rests on valuation and the business; the model supports patience through the earnings event rather than offering a reason to chase it before results.
March-quarter free cash flow was negative $291 million, which means cash conversion deserves attention on July 23. Program timing, cost overruns, budget politics, and supply-chain execution are real risks. BUY: accumulate below the mean target framework, with the $627.10 consensus target as the base reference. Treat the $700 high target as an upside case, not the underwriting case.

2. Stryker (SYK) — BUY

Stryker is a profitable medtech business with an entry price that reflects uncertainty more than a collapse in the underlying operating engine. In the March quarter, revenue was $6.020 billion, operating income was $936 million, net income was $745 million, and free cash flow was $415 million. The company reports July 30, when consensus expects $3.46 of EPS and $6.580 billion of revenue. This is a business that can compound through product adoption, procedure volume, and operating execution; it does not need a broad healthcare ETF breakout for its own fundamentals to improve.
SYK closed at $319.87, 19.4% below its $381.79 mean target, with a published range of $315 to $465. Technically, the stock is above its 50-day average but below the 200-day average. That supports an accumulation thesis with defined risk rather than a momentum thesis. The approximate 21.4x forward P/E is not a bargain multiple, but it is more reasonable when paired with a profitable business and a nearly 20% discount to consensus.
The 1D forecast is UP 0.16% to $320.39 at 66.79% confidence for July 20. The 3D forecast is UP 0.04% to $319.99 at 66.52% confidence for July 22. The 7D forecast is UP 0.21% to $320.53 at 82.54% confidence for July 28. We agree with the direction, while recognizing that the model’s forecasted short-horizon returns are small. It supports an orderly entry; it does not promise a fast rerating. The high-confidence 7D read is constructive, but the fundamental catalyst remains July 30 earnings.
Procedure volumes, reimbursement, foreign exchange, and execution on product cycles can change the operating path. A miss or softer guidance on July 30 could send the stock toward the $315 low-target area. BUY: the $381.79 mean target is the medium-term reference. Position sizing should recognize that the entry is close to earnings and that the 1D/3D readings are still below 70% confidence.

3. S&P Global (SPGI) — BUY

S&P Global is the information-services choice in a market where investors are questioning the durability of the most crowded hardware trades. Its March-quarter revenue was $4.171 billion, operating income was $2.002 billion, net income was $1.395 billion, and free cash flow was $1.010 billion. The business is not immune to credit markets, issuance activity, or macro volatility, but it has diversified data, benchmarks, ratings, and analytics franchises that create recurring demand beyond one technology spending cycle.
The stock’s 4.72% weekly gain deserves a caveat. SPGI is above both its 50-day average of $404.30 and 200-day average of $436.26, so it is not a technical reset in the way LMT is. The reason it remains a BUY is valuation relative to consensus: its $541.22 mean target is 20.0% above the $450.84 close, with a published range of $498 to $625. This is a long-term valuation opportunity in a company that has shown relative resilience, not a bargain-basement entry.
The 1D model is UP 0.07% to $451.17 at 53.85% confidence for July 20. The 3D model is UP 0.08% to $451.20 at 73.34% confidence for July 22. The 7D model is UP 0.15% to $451.53 at 64.21% confidence for July 28. We agree with the direction but do not overread the percentages. The forecasted moves are modest, and only the 3D confidence clears 70%. The model confirms that the near-term path is not actively fighting the long-term thesis; it does not create the thesis.
Credit-market issuance, regulatory scrutiny, financial-market volumes, and a weaker macro environment can all affect the earnings path. The July 28 report is both a catalyst and a risk event. BUY: use the $541.22 mean target as the base case and $625 only as the optimistic endpoint. The stock should be owned for a durable information-services franchise and a 20.0% target gap, not because it was green in a weak week.

6. Low-Cap Opportunities

StockResearch Intelligence Weekly #25, graphic 4

1. Modine Manufacturing (MOD) — SPEC. BUY

Modine offers a direct industrial cooling and data-center capacity story, but the verdict is deliberately speculative because valuation and execution are both demanding. Its fiscal fourth-quarter revenue was $954.4 million, up 47% year over year. Net income was $73.6 million and diluted EPS was $1.36; adjusted EPS was $1.71, up 53%. The company guided fiscal 2027 sales growth to 20%-35% and adjusted EBITDA to $650-$680 million. Those are concrete operating claims, not a generic AI-label narrative.
At $229.34, MOD is 56.2% below its $358.17 mean target. The published target range is $325 to $428. The stock is below its 50-day average of $266.41 but above its 200-day average of $201.59 after falling 6.74% this week. That arrangement can support a recovery, but it also signals that investors are reassessing the premium placed on growth. The July 28 earnings report, with consensus for $1.38 EPS and $891.2 million of revenue, is the next moment where the market can decide whether the capacity and data-center growth story is translating into sustainable margins.
Gross margin fell 320 basis points to 22.5% in the reported quarter as temporary capacity, tariffs, and material costs weighed. This is not a detail to bury beneath the target gap. A high multiple can contract quickly if growth remains strong but margins fail to recover. SPEC. BUY: the $358.17 mean target supplies a compelling upside reference, but the position belongs in a smaller, catalyst-aware allocation rather than a core sleeve.

2. CAVA Group (CAVA) — HOLD

CAVA’s operating momentum is better than its HOLD label might imply. In the latest reported quarter, the company delivered revenue of $434.4 million, up 32.2%, same-restaurant sales growth of 9.7%, and traffic growth of 6.8%. Restaurant-level profit margin was 25.1%, adjusted EBITDA was $61.7 million, and the company opened 20 net new restaurants. CAVA’s first-quarter release describes a growth business with genuine unit expansion and healthy restaurant economics.
The valuation is the problem, not the operating quality. At $68.85, the stock is 35.3% below the $93.18 mean target, with a $74 to $106 published range. Yet it trades at approximately 124.5x FY2026 consensus EPS and is below both moving averages. A 35% target gap is meaningful, but not large enough to make that multiple disappear; a high-expectations restaurant growth name can reprice hard if same-store sales or new-unit productivity softens.
The August 11 report is the next real proof point. We need continued traffic, unit-level margin discipline, and a credible pace of openings. HOLD: existing owners have a reasonable target framework, but new money should wait for a better valuation or a lower-risk post-earnings entry. The company is strong; the price is still asking for a lot.

3. IonQ (IONQ) — NO TRADE

IonQ is the cleanest example of why a large target gap must not be treated as a buy signal. The share price is 93.0% below its $67.13 mean target, with published targets from $48.50 to $85. Revenue in the March quarter was $64.7 million, up 755%, and the company raised FY2026 revenue guidance to $260-$270 million. It also reported $3.1 billion of cash and investments. IonQ’s first-quarter release gives the growth narrative and balance-sheet optionality real support.
The missing piece is profitability and execution visibility. FMP consensus expects a FY2026 loss of $0.37 per share. March-quarter operating cash flow was negative $151.0 million and free cash flow was negative $159.4 million. The company reported an adjusted EBITDA loss of $96.8 million for the quarter and guided to a full-year adjusted EBITDA loss of $310-$330 million. The stock fell 18.85% this week and is below both its 50-day and 200-day averages. A target gap that large may be opportunity, but it can also reflect a valuation built on years of future outcomes.
Commercial conversion, acquisitions, technology roadmap execution, cash burn, and competition are all active risks. The August 5 earnings report may clarify the revenue path, but it does not make the existing loss profile disappear. NO TRADE: monitor the business, do not underwrite the $67.13 target as though it were a cash-flow forecast. We need evidence that revenue growth can translate into a more durable economics before taking the valuation risk.

7. Strategic Recap & Forward Outlook

This was a selective reset, not a blanket verdict on equities. The market cut semiconductor and AI-infrastructure exposure hard while allowing energy and selected information-services businesses to hold up. That makes stock selection more useful than index chasing. Our response is to buy where the consensus gap is supported by a profitable business and a visible catalyst: LMT, SYK, and SPGI. In low caps, we accept MOD’s growth opportunity only with speculative sizing, retain CAVA as a HOLD because the multiple is still demanding, and leave IONQ alone until the economics catch up with the narrative.

The model reinforces rather than dictates that stance. LMT, SYK, and SPGI have UP signals at every horizon, but only selected horizons clear 70% confidence. It can challenge timing and conviction; it cannot erase a weak entry, negative cash flow, or earnings risk.

Forward Outlook

Monday, July 20: The Conference Board’s June Leading Economic Index is scheduled at 10:00 a.m. ET.
Wednesday, July 22: Tesla reports second-quarter results after the close. Tesla investor relations
Thursday, July 23: Lockheed Martin reports second-quarter results at 8:30 a.m. ET, alongside weekly jobless claims.
Friday, July 24: S&P Global flash U.S. manufacturing and services PMIs arrive at 9:45 a.m. ET, followed by June new-home sales at 10:00 a.m. ET. S&P Global PMI calendar
Tuesday-Wednesday, July 28-29: The FOMC meets; SPGI, MOD, and then SYK earnings, GDP, and PCE follow in the same week.

Disclaimer: StockResearch Intelligence Weekly is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. All data is sourced from third-party providers and believed accurate as of the publication date but is not guaranteed. Price targets and verdicts reflect the author’s analysis and may change without notice. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Conduct your own research and consult a licensed financial advisor before making investment decisions. The author may hold positions in securities mentioned.*

This article is research and education, not investment advice. Past performance does not guarantee future results.